The bradykinin/soluble guanylate cyclase signaling pathway is impaired in androgen-independent prostate cancer cells

Cancer Lett. 2002 Mar 28;177(2):181-7. doi: 10.1016/s0304-3835(01)00788-1.

Abstract

The activation of soluble guanylate cyclase by bradykinin and sodium nitroprusside (SNP), a direct activator of soluble guanylate cyclase, was evaluated in androgen-sensitive LNCaP and androgen-independent PC3 and DU145 prostate cancer cells. Bradykinin and SNP activated soluble guanylate cyclase in LNCaP cells, but not in PC3 and DU145 cells. Western blot analysis revealed that the bradykinin B2 receptor, Gqalpha, phospholipase Cgamma and endothelial nitric oxide synthase were expressed in LNCaP, PC3 and DU145 cells. However, both Western blotting and reverse transcriptase--polymerase chain reaction indicated that soluble guanylate cyclase was only expressed in LNCaP cells. These results demonstrate that the impaired bradykinin-soluble guanylate cyclase pathway in PC3 and DU145 cells is likely due to lack of expression of soluble guanylate cyclase.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Androgens / metabolism
  • Bradykinin / metabolism*
  • Guanylate Cyclase / metabolism
  • Humans
  • Male
  • Neoplasms, Hormone-Dependent / metabolism
  • Prostatic Neoplasms / metabolism*
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Signal Transduction*
  • Soluble Guanylyl Cyclase
  • Tumor Cells, Cultured

Substances

  • Androgens
  • Receptors, Cytoplasmic and Nuclear
  • Guanylate Cyclase
  • Soluble Guanylyl Cyclase
  • Bradykinin